Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment A retrospective multicenter study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Myungsun | - |
dc.contributor.author | Kim, Jong Keun | - |
dc.contributor.author | Bang, Woo Jin | - |
dc.contributor.author | Lee, Yong Seong | - |
dc.contributor.author | Cho, Sung Tae | - |
dc.contributor.author | Cho, Jin Seon | - |
dc.contributor.author | Joo, Kwan Joong | - |
dc.contributor.author | Hyun, Jae Seog | - |
dc.contributor.author | Kim, Byung Hoon | - |
dc.contributor.author | Lee, Jong Bok | - |
dc.contributor.author | Seo, Young Jin | - |
dc.contributor.author | Oh, Cheol Young | - |
dc.date.accessioned | 2024-07-01T02:30:46Z | - |
dc.date.available | 2024-07-01T02:30:46Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74451 | - |
dc.description.abstract | Purpose: To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics. Materials and Methods: We retrospectively reviewed the data of 566 male patients aged >= 40 with OAB symptoms between January 2017 and June 2018. They were treated with low-dose antimuscarinics for at least 4 weeks and showed poor efficacy; therefore, they were switched to standard dose antimuscarinic treatment (5 mg of solifenacin) for >= 12 weeks. The international prostate symptom score (IPSS) and overactive bladder symptom score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Post void residual urine volume (PVR) was also recorded. Results: The median age, body mass index, and prostate-specific antigen levels were 69.0 years, 24.2 kg/m(2), and 1.24 ng/dL, respectively. The mean value of the total IPSS and OABSS significantly decreased between V0 and V2 (from 16.73 to 13.69 and 7.33 to 5.34, respectively, all p<0.001). All component scores from each questionnaire demonstrated a significant decrease except for numbers three and six on the IPSS questionnaire. PVR was increased from V0 to V2 (36.40 to 68.90 mL, p=0.015). Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as <= 2. Conclusions: Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN UROLOGICAL ASSOC | - |
dc.title | Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment A retrospective multicenter study | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.20200053 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, v.61, no.6, pp 600 - 606 | - |
dc.identifier.kciid | ART002644387 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000583792000008 | - |
dc.identifier.scopusid | 2-s2.0-85094875147 | - |
dc.citation.endPage | 606 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 600 | - |
dc.citation.title | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.volume | 61 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Muscarinic antagonists | - |
dc.subject.keywordAuthor | Prostatic hyperplasia | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.subject.keywordAuthor | Urinary bladder | - |
dc.subject.keywordAuthor | overactive | - |
dc.subject.keywordPlus | URINARY-TRACT SYMPTOMS | - |
dc.subject.keywordPlus | OUTLET OBSTRUCTION | - |
dc.subject.keywordPlus | TAMSULOSIN | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | SOLIFENACIN | - |
dc.subject.keywordPlus | INCONTINENCE | - |
dc.subject.keywordPlus | TOLTERODINE | - |
dc.subject.keywordPlus | STORAGE | - |
dc.subject.keywordPlus | BPH | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.